Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07329712

Enrollment

Registered

2026-01-09

Start date

2025-11-05

Completion date

2027-12-31

Last updated

2026-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye, Meibomian Gland Dysfunction (Disorder)

Keywords

Dry Eye, low level light therapy, Eyelight, Tears proteomics, tear cytokine, MGD

Brief summary

The purpose of this research study is to understand the mechanism of action of low level light therapy and also potentially yield markers associated with good treatment response. Low-level light therapy is light-based treatment delivered through advance eye-light device. This therapy uses light energy to provide energy to the meibomian gland cells to slow down age-ing, improve tear stability and reduce inflammation.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Must be eligible for, and have consented for low level light therapy 2. Must not have presented to the clinic for an acute eye problem such as visual loss or painful eye 3. Ability to give informed consent. 4. Age more or equals to 21 years old.

Exclusion criteria

1. Patients who are unable to or decline to give consent. 2. Age less than 21 years old. 3. Patients who presented to the clinic for an acute eye problem such as visual loss or painful eye. 4. Patients not suitable for low level lighttherapy: * Pregnant * Fitted with pacemakers, metal, electrical, acoustic prosthetics * Epilepsy, cardiac rhythm or frequency disorders * Fever, thrombophlebitis or acute phlebitis of the legs, large-sized varicose veins, or venous surgery within 2 months * Uncontrolled hypertension or severe diabetes * Open wounds on eyelid or skin * Evolving cancer or hepatitis * Blood anticoagulant or coagulation defect

Design outcomes

Primary

Measure	Time frame	Description
Comparing tear proteomics profile in dry eye disease pre-and post-treatment with low level light therapy	Baseline visit and Post Baseline visit 3 months (+3 weeks).	Aim 1: Tear proteomic profile of MGD patients with DED pre- and post-treatment with LLLT will be profiled Aim 2: Baseline tear cytokine levels will be measured using the novel Olink 500-plex technology in DED patients with MGD undergoing LLLT

Countries

Singapore

Contacts

Primary ContactLouis Tong Tong, PhD

louis.tong.h.t@singhealth.com.sg65767200

Backup ContactJiayi Lee, MSc

lee.jiayi1@singhealth.com.sg

Outcome results